Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) had its target price reduced by stock analysts at Goldman Sachs Group Inc. from $65.00 to $34.00 in a note issued to investors on Thursday, StockTargetPrices.com reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. Goldman Sachs Group Inc.’s price objective suggests a potential downside of 51.64% from the company’s previous close.
A number of other equities analysts have also weighed in on the company. Needham & Company LLC reiterated a “buy” rating and set a $152.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, August 5th. Cowen and Company reiterated a “buy” rating and set a $150.00 target price on shares of Alnylam Pharmaceuticals in a research note on Sunday, August 7th. Jefferies Group set a $86.00 target price on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, September 28th. Janney Montgomery Scott started coverage on Alnylam Pharmaceuticals in a research note on Wednesday, September 28th. They set a “neutral” rating and a $74.00 target price on the stock. Finally, Zacks Investment Research upgraded Alnylam Pharmaceuticals from a “sell” rating to a “buy” rating and set a $85.00 target price on the stock in a research note on Tuesday, August 9th. Seven research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $94.31.
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 46.93% during trading on Thursday, reaching $37.31. The company’s stock had a trading volume of 7,812,253 shares. Alnylam Pharmaceuticals has a 1-year low of $35.31 and a 1-year high of $110.75. The stock’s market cap is $3.20 billion. The company’s 50 day moving average price is $72.86 and its 200-day moving average price is $66.46.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.24) by $0.19. The firm had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.09 million. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The business’s revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.85) earnings per share. Equities analysts forecast that Alnylam Pharmaceuticals will post ($4.64) earnings per share for the current fiscal year.
In related news, CEO John Maraganore sold 30,151 shares of the firm’s stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the sale, the chief executive officer now owns 148,465 shares of the company’s stock, valued at approximately $9,604,200.85. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 4.00% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP increased its stake in Alnylam Pharmaceuticals by 12.1% in the first quarter. Wellington Management Group LLP now owns 11,945,607 shares of the biopharmaceutical company’s stock valued at $749,826,000 after buying an additional 1,288,123 shares during the period. Vanguard Group Inc. increased its stake in Alnylam Pharmaceuticals by 3.5% in the second quarter. Vanguard Group Inc. now owns 5,385,509 shares of the biopharmaceutical company’s stock valued at $298,843,000 after buying an additional 182,614 shares during the period. Baillie Gifford & Co. increased its stake in Alnylam Pharmaceuticals by 0.3% in the second quarter. Baillie Gifford & Co. now owns 3,390,252 shares of the biopharmaceutical company’s stock valued at $188,125,000 after buying an additional 10,317 shares during the period. Dodge & Cox purchased a new stake in Alnylam Pharmaceuticals during the second quarter valued at $139,650,000. Finally, State Street Corp increased its stake in Alnylam Pharmaceuticals by 13.4% in the second quarter. State Street Corp now owns 2,195,504 shares of the biopharmaceutical company’s stock valued at $121,832,000 after buying an additional 258,984 shares during the period. 85.96% of the stock is currently owned by institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.